The US conditional approval pathway has enjoyed years of expansion, but now the FDA is trying to put the toothpaste back into the tube.
Attempts to raise a personalised immune response against neoantigens have attracted big pharma interest, most recently from Merck & Co.
Inhibition of Kras dominated Esmo, though probably not in the way some had hoped.
But progress – or lack thereof – with lenacapavir is a more immediate concern.
Find out where the venture money has been flowing in our new report on biopharma investment trends, free to download now.
Though current vaccines show efficacy, work on next-generation iterations against the South Africa variant is under way.